Fluzoparib Capsules is a PARP inhibitor primarily indicated for the treatment of specific types of malignant tumors including ovarian cancer and breast cancer. Its common adverse reactions involve the hematological system, digestive system and systemic responses. Dosage adjustments should be made based on individual conditions, and the medication must be taken strictly as prescribed by a physician with regular clinical monitoring.
I. Common Adverse Reactions and Corresponding Management Measures
1. Hematological Abnormalities
Anemia
Manifested as fatigue and dizziness. Regular complete blood count (CBC) monitoring is required; blood transfusion or dosage adjustment may be implemented if necessary.
Thrombocytopenia
May induce bleeding tendency. Avoid bumps and bruises, and temporary treatment discontinuation is indicated in severe cases.
Neutropenia
Elevates the risk of infection. Immediate medical attention is needed if symptoms such as fever develop.
2. Gastrointestinal Reactions
Nausea and vomiting
Can be alleviated through dietary adjustments or the administration of antiemetic drugs.
Diarrhea or constipation
Maintain a light diet; symptomatic medications may be used if needed.
3. Systemic Symptoms
Fatigue
Appropriate rest is recommended, and overexertion should be avoided.
Anorexia
Adopt a pattern of small, frequent meals and choose high-nutrient foods.
II. Severe Adverse Reactions Requiring Vigilant Monitoring
Myelosuppression
May lead to severe anemia, infection or bleeding, for which immediate medical intervention is mandatory.
Hepatic and Renal Dysfunction
Monitor hepatic and renal function indicators on a regular basis. Discontinue the medication if symptoms such as jaundice or reduced urine output occur.
Allergic Reactions
Such as skin rashes and dyspnea, which are rare but require emergency management.
III. Other Precautions
Drug Interactions
Concomitant use with potent CYP3A4 inhibitors (e.g., ketoconazole) should be avoided, as this may impair the therapeutic effect of the drug.
Special Populations
The medication is contraindicated in pregnant women and lactating females; dosage adjustment is required for patients with hepatic or renal insufficiency.
IV. Principles of Medication Use
Follow Physician Instructions Strictly
Do not increase, decrease the dosage or discontinue the medication without professional advice.
Regular Follow-up Visits
Undergo rechecks of complete blood count and hepatic/renal function every 2 to 4 weeks during the treatment course.
Prompt Symptom Feedback
Immediately contact the treating physician if symptoms such as persistent vomiting, high fever or abnormal bleeding occur.
For long-term medication use, physicians will evaluate and adjust the treatment regimen based on therapeutic efficacy and the occurrence of adverse reactions. Patients are advised to maintain close communication with their medical team and document all physical responses to the medication.
